<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsFei Su, Jeffrey A. Sosman, Amaya Virós et al.|New England Journal of Medicine|2012Cited by 1k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Shreyaskumar Patel, Axel Le Cesne et al.|The Lancet|2016Cited by 766
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S. Grasso, Antoni Ribas, Jennifer Tsoi et al.|Cancer Cell|2020Cited by 379
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodiesAlain P. Algazi, Ryan J. Sullivan, Katy K. Tsai et al.|Cancer|2016Cited by 375
Non-viral precision T cell receptor replacement for personalized cell therapySusan P. Foy, Stefanie Mandl, James R. Heath et al.|Nature|2022Cited by 276